Skip to main content
Clinical Trials/NCT02056912
NCT02056912
Completed
Not Applicable

Identification of a New Gene Involved in Hereditary Lipodystrophy - LIPOGENE

University Hospital, Bordeaux1 site in 1 country2 target enrollmentJanuary 2014
ConditionsLipodystrophy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lipodystrophy
Sponsor
University Hospital, Bordeaux
Enrollment
2
Locations
1
Primary Endpoint
Additional mutation in the studied candidate gene XX
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Human lipodystrophies (lipoD) represent a heterogeneous group of diseases characterized by generalized or partial fat loss, with fat hypertrophy in other depots when partial.3, 4 Insulin resistance, dyslipidemia and diabetes are generally associated, leading to early complications. Acquired lipoD can be generalized, resembling congenital forms, or partial, as the Barraquer-Simons syndrome, with loss of fat in the upper part of the body contrasting with accumulation in the lower part. The most common forms of lipoD are iatrogenic. In human immunodeficiency virus-infected patients, some first-generation antiretroviral drugs were strongly related with peripheral lipoatrophy and metabolic alterations. Genetic forms are very uncommon: recessive generalized congenital lipoD result in most cases from mutations in the genes encoding seipin or the 1-acyl-glycerol-3-phosphate-acyltransferase 2 (AGPAT2). Dominant partial familial lipoD result from mutations in genes encoding the nuclear protein lamin A/C or the adipose transcription factor PPARgamma. Importantly, LMNA mutations are also responsible for metabolic laminopathies, resembling the metabolic syndrome and progeria, a syndrome of premature aging. Molecular genetic bases of many rare forms of genetic lipoD remain to be elucidated.

Detailed Description

The investigators have recently evaluated two sisters (index patients) affected by a syndrome associating diffuse leukoencephalopathy and partial lipoD. The investigators have analyzed numerous known genetic causes of leukodystrophies and lipoD but the investigators failed to identify a known cause for this syndrome which has never been previously reported. The investigators then switched their effort to analyses of exome using next generation sequencing in both affected sisters and their unaffected relatives (one sister and two parents). The investigators identified an excellent candidate gene with a homozygous missense mutation in both affected sisters. The investigators now aim to prove the involvement of this candidate gene in lipoD's determinism by a search of additional mutations in the candidate gene in a series of patients affected with lipoD (collaboration with Pr Capeau's Team) (LIPOGENE study) and by functional analyses performed in the two index patients on blood and skin samples (LIPOGENE sub-study).

Registry
clinicaltrials.gov
Start Date
January 2014
End Date
January 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital, Bordeaux
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients affected by lipoD
  • No identified genetic cause of lipoD
  • Child or adult
  • DNA already available in the French reference laboratory for the genetic diagnosis of lipoD (laboratoire de Biochimie du CHU Saint-Antoine, Paris) or in the INSERM UMRS 938 laboratory, Faculté de médecine Pierre et Marie Curie Site Saint-Antoine, Paris
  • Subject affiliated to the french Sécurité Sociale
  • Signed consent obtained for the molecular diagnosis of lipoD.
  • Signed consent obtained for this sub-study from both index patients

Exclusion Criteria

  • Identified genetic cause of lipoD
  • No signed consent by the patient
  • Subject not affiliated to the french Sécurité Sociale.
  • Absence of signed consent obtained for this sub-study from both index patients

Outcomes

Primary Outcomes

Additional mutation in the studied candidate gene XX

Time Frame: 6 months

Study's primary outcome

Phospholipids anomalies in plasma

Time Frame: 6 months

Sub-study's primary outcome

Dense deposits in fibroblasts cytoplasm

Time Frame: 6 months

Sub-study's primary outcome

Quantitative or qualitative variation of the protein encoded by the candidate gene in fibroblasts

Time Frame: 6 months

Sub-study's primary outcome

Altered lipids composition in blood red cells membranes

Time Frame: 6 months

Sub-study's primary outcome

Study Sites (1)

Loading locations...

Similar Trials